Eucrisa (Crisaborole) Patent Expiration, LOE Window & CMS Spending
Eucrisa (Crisaborole) by Anacor: FDA Orange Book core substance LOE 2029-12-29 (last listed 2030-07-20), 1 AB generics, $77.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Anacor |
| FDA Application & Pathway | N207695 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2029-12-29 |
| Last Listed Patent or Exclusivity Date | 2030-07-20 |
| Orange Book Patents (*PED Extensions) | 8 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $77.0M |
| 2024 Medicare Part D Spend | $9.3M |
| 2024 Medicaid Spend | $67.8M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 14.7% 2-yr change) |